Dr. Reisner is chair of the scientific advisory board for Cell Source and has equity in the company. These financial relationships have been disclosed to MD Anderson's Conflict of Interest Committee ...

Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, ...

Hans Lee, MD, explores how minimal residual disease (MRD) testing guides treatment decisions for multiple myeloma and highlights the value of patient preferences.

Called cryoablation, the procedure has not been federally approved for breast cancer treatment, but clinical trials are ...

From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.

In 17 heavily pretreated NSCLC EGFR mutant (EGFR mut) patients the combination shows an ORR of 24% and a DCR of 71%; tumor ...

Aucatzyl is a chimeric antigen receptor (CAR) T-cell therapy, a type of therapy that uses genetic modification to train the ...

A study led by Roswell Park provides new insight into the complex interactions of the "tumor-immune-gut axis," and its role in influencing immunotherapy responses in patients with recurrent ovarian ...

Patients with early breast cancer who skipped axillary lymph node dissection (ALND) lived just as long as those who underwent ...

Updated Phase 1 data include a 16.3-month median recurrence-free survival ("mRFS") and 28.9-month median overall survival ("mOS") from full study population Strong correlation observed between mRFS an ...

The HER2-low and HER2-ultralow breast cancer subtype designations have led to a changed landscape in HER2-directed therapies, ...

Lauren Averett Byers, M.D., professor of Thoracic/Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer ...